Telephone: (800) 514-0083 option 2
Fax: (866) 374-1579

Palivizumab (Synagis)

Prior Authorization Form/ Prescription

Date: ___________ Date Medication Required:____________
Ship to: ❍ Physician ❍ Patient's Home ❍ Other __________

Patient Information

Last Name:	First Name:	Middle:	DOB: ____/____/_____
Address:	City:	State:	Zip:
Daytime Phone:	Evening Phone:	Sex: ☐ Male ☐ Female	

Insurance Information (Attach Copies of cards)

Primary Insurance:		Secondary Insurance:	
ID #	Group #	ID #	Group #
City:	State:	City:	State:

Physician Information

Name:	Specialty:	NPI:	
Address:	City:	State:	Zip:
Phone # ( )	Secure Fax #: ( )	Office contact:	

Primary Diagnosis

ICD-10 Code: ________________________

- ☐ Congenital Heart Disease
- ☐ Chronic Respiratory disease arising in the perinatal period
- ☐ Congenital Abnormality of Respiratory System
- ☐ Cystic Fibrosis
- ☐ < 24 weeks of gestation
- ☐ 24 weeks gestation
- ☐ 25-26 weeks of gestation
- ☐ 27-28 weeks of gestation
- ☐ 29-30 weeks of gestation
- ☐ 31-32 weeks of gestation
- ☐ 33-34 weeks of gestation
- ☐ 35-36 weeks of gestation
- ☐ 37+ weeks of gestation
- ☐ Other ________________

Clinical Information ***** Please submit supporting clinical documentation*****

Patient's gestational age (Required): __________weeks ___________days Birth Weight: ________ g/kg/lbs Current Weight: ________ g/kg/lbs Date Recorded: ______________

Did the patient spend time in the NICU? ☐ Yes ☐ No ***If yes, provide NICU name and attach discharge summary:*** ____

Was this season's first Synagis dose given in the NICU? ☐ Yes ☐ No ***If yes, provide date(s):*** __________________ Expected date of first/next injection: ____________________

Patient Evaluation (Check all that apply and submit clinical documentation):

☐ Hospitalization for RSV infection this season?

☐ Diagnosis of hemodynamically significant Congenital Heart Disease (CHD) and < 12 months of age at start of RSV Season and patient has the following conditions (Check all that apply):
- ☐ Moderate-Severe Pulmonary Hypertension
- ☐ Cyanotic Heart Disease (if consulted with a pediatric cardiologist)
- ☐ Acyanotic heart disease medications to control CHF (list medications): ______________ Last Date Received: ____________ AND require cardiac surgical procedures

☐ Diagnosis of Chronic Lung Disease* and less than 12 months at start of RSV Season
*CLD is generally defined as: Infants <32 weeks, 0 days with oxygen requirement > 21% for at least the first 28 days of birth. CLD is NOT defined as asthma, croup, recurrent upper respiratory infections, chronic bronchitis, bronchiolitis, or a history of a previous RSV infection

☐ Diagnosis of Chronic Lung Disease* and between 12 to less than 24 months at start of RSV Season and receiving treatment of (check all that apply and provide last date received):
- ☐ Supplemental oxygen, Date:_________________
- ☐ Chronic corticosteroid therapy, Date: _________________
- ☐ Diuretic therapy, Date: _________________

☐ Diagnosis of Cystic Fibrosis and less than 12 months of age at start of RSV season?
- ☐ Clinical evidence of CLD
- ☐ Nutritional compromise: Explain: ____

☐ Diagnosis of Cystic Fibrosis and between 12 to less than 24 months of age at start of RSV season
- ☐ Manifestations of severe lung disease (hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or CT that persists when stable)
- ☐ Weight for length less than 10th percentile

☐ Diagnosis of condition that impairs the ability to clear secretions from the upper airway because of ineffective cough ***AND*** less than 12 months at the start of RSV season
- ☐ Congenital anomaly that impairs the ability to clear secretions from the upper airway because of ineffective cough
- ☐ Neuromuscular condition

☐ Patient be profoundly immunocompromised during the RSV season (e.g., due to solid organ or hematopoietic stem cell transplantation, chemotherapy, severe combined immunodeficiency, chronic granulomatous disease). **If yes, provide chart notes documenting care plan**

☐ Patient is an Alaska native or American Indian.

Please list other medical history and/or risk factors: ____

Home Health Coordination

Please note, separate authorization is required for injection training/home health visit. Call (866) 296-8731 for prior authorization

☐ Specialty Pharmacy to coordinate injection to coordinate injection training/home health nurse visit as necessary. Please list Agency of choice: ______________________________

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
Synagis	☐50mg ☐100mg	**Inject 15 mg/kg IM one time per month**		

☐ Prescriber has counseled parent/guardian on Synagis therapy and the specialty pharmacy may contact parent/guardian

Physician's Signature ____ **Date:** ______________________ ☐ DAW